CRIS Current Research Information System

TOVOLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.643
NA - Nord America 8.531
EU - Europa 5.387
AF - Africa 536
SA - Sud America 492
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 1
Totale 25.604
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.347
VN - Vietnam 3.023
CN - Cina 2.739
SG - Singapore 2.615
IT - Italia 1.403
GB - Regno Unito 754
DE - Germania 736
SE - Svezia 587
HK - Hong Kong 549
KR - Corea 370
IN - India 344
BR - Brasile 336
BD - Bangladesh 334
FR - Francia 321
NL - Olanda 269
RU - Federazione Russa 234
IE - Irlanda 231
FI - Finlandia 230
JP - Giappone 169
TG - Togo 149
CH - Svizzera 138
ZA - Sudafrica 117
CA - Canada 97
CI - Costa d'Avorio 97
UA - Ucraina 75
PH - Filippine 73
ID - Indonesia 70
SC - Seychelles 70
AR - Argentina 61
AT - Austria 61
BG - Bulgaria 58
TH - Thailandia 51
PK - Pakistan 50
MX - Messico 48
EE - Estonia 46
TR - Turchia 40
IQ - Iraq 39
JO - Giordania 38
TW - Taiwan 37
PL - Polonia 36
ES - Italia 35
BE - Belgio 33
NG - Nigeria 30
HR - Croazia 25
CL - Cile 22
CO - Colombia 20
EG - Egitto 20
UZ - Uzbekistan 20
EC - Ecuador 16
LT - Lituania 15
MA - Marocco 15
RO - Romania 15
VE - Venezuela 15
CZ - Repubblica Ceca 13
GR - Grecia 13
SA - Arabia Saudita 13
DZ - Algeria 11
MK - Macedonia 11
MY - Malesia 11
PT - Portogallo 9
AZ - Azerbaigian 8
KE - Kenya 8
AL - Albania 7
AU - Australia 7
JM - Giamaica 7
LV - Lettonia 7
PY - Paraguay 7
CR - Costa Rica 6
DK - Danimarca 6
HN - Honduras 6
LB - Libano 6
PS - Palestinian Territory 6
SV - El Salvador 6
UY - Uruguay 6
HU - Ungheria 5
KZ - Kazakistan 5
NP - Nepal 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 3
IR - Iran 3
MD - Moldavia 3
OM - Oman 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AO - Angola 2
BB - Barbados 2
BF - Burkina Faso 2
CM - Camerun 2
CY - Cipro 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PR - Porto Rico 2
Totale 25.574
Salva come PNG Salva come JPEG
Città #
Singapore 1.813
Ashburn 1.089
Ho Chi Minh City 743
Hefei 736
Hanoi 695
Fairfield 640
Southend 597
San Jose 541
Chandler 526
Hong Kong 483
Bologna 377
Santa Clara 370
Seoul 326
Woodbridge 295
Wilmington 278
Seattle 275
Beijing 267
Houston 254
Boardman 244
Dublin 229
Dong Ket 223
Cambridge 203
Princeton 203
Los Angeles 196
Council Bluffs 194
New York 177
Helsinki 172
Ann Arbor 160
Dallas 157
Munich 152
Lomé 149
Lauterbourg 146
Da Nang 134
Tokyo 131
Bern 125
Haiphong 113
Milan 101
Abidjan 97
Buffalo 79
Frankfurt am Main 79
Rome 77
São Paulo 77
Redondo Beach 75
Berlin 67
Bengaluru 63
Westminster 61
Guangzhou 56
Nanjing 54
Turin 53
Chicago 52
Shanghai 52
Sofia 52
Johannesburg 50
Padova 50
Amsterdam 45
Orem 43
Jinan 42
Hải Dương 41
Amman 38
Bremen 38
San Diego 38
Vienna 37
Jakarta 36
London 36
Can Tho 35
Nuremberg 35
Lappeenranta 34
Shenyang 33
Des Moines 32
Redmond 32
Falkenstein 31
Brussels 30
Florence 30
Lahore 30
Toronto 29
Abeokuta 28
Phoenix 28
Tianjin 28
Warsaw 28
Washington 28
Biên Hòa 27
Redwood City 27
Saint Petersburg 27
Tongling 27
Changsha 26
Jacksonville 25
Montreal 24
Shenzhen 24
The Dalles 24
Ninh Bình 23
Brooklyn 21
Nha Trang 21
Vũng Tàu 21
Baghdad 20
Bến Tre 20
Falls Church 20
Mexico City 20
San Francisco 20
Thái Nguyên 20
Turku 20
Totale 15.950
Salva come PNG Salva come JPEG
Nome #
Serological tests in gluten sensitivity (nonceliac gluten intolerance). 450
Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods 318
Monofocal hepatocellular carcinoma: How much does size matter? 295
Ablation for hepatocellular carcinoma: beyond the standard indications 269
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 267
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 267
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 257
Pattern of macrovascular invasion in hepatocellular carcinoma 242
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 235
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 234
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 233
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 225
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 223
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 222
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 215
Current guidelines for the management of celiac disease: A systematic review with comparative analysis 213
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 213
A case of inflammatory ascites. 211
The changing scenario of hepatocellular carcinoma in Italy: an update 209
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 209
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 206
Evaluation of Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Sprague-Dawley Rats Treated with Low Doses of Aflatoxin B1 Alone or in Combination with Extremely Low Frequency Electromagnetic Fields 204
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 201
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 200
Metabolic disorders across hepatocellular carcinoma in Italy 200
Clinical and diagnostic aspects of gluten related disorders 197
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 196
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 195
An uncommon focal liver lesion: Intrahepatic splenosis 192
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 191
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 188
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 187
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 186
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 185
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 184
Should patients on levothyroxine therapy be screened for pancreatic cancer? 183
A seroimmunological profile of erosive hand osteoarthritis. 183
Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic eraThe views of a panel of worldwide international experts 182
Donafenib in hepatocellular carcinoma 181
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma 180
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 179
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 177
Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers 176
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 176
COVID-19: Has the Liver Been Spared? 176
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 174
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 174
Imaging of colorectal liver metastases: New developments and pending issues 174
Cholangiocarcinoma: From risk to prevention? 173
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors 173
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 170
Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. 169
Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients? 168
More therapeutic alternatives for chronic idiopathic urticaria? 167
Thrombotic thrombocytopenic purpura mimicking an acute meningoencephalitis. 167
null 164
From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma 164
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 163
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 162
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 162
Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient. 160
TKIs in combination with immunotherapy for hepatocellular carcinoma 160
Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for {COVID}-19 Pandemic 159
Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. 158
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives 158
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 157
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 156
Autoimmune liver disorders and small-vessel vasculitis:four case reports and review of the literature 156
Treatment of combined hepatocellular and cholangiocarcinoma 155
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 154
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 153
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 152
Rheumatoid arthritis: New monoclonal antibodies 152
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 152
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 151
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 151
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 150
Experience with regorafenib in the treatment of hepatocellular carcinoma 149
Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma 144
Old and new serological tests for celiac disease screening. 143
Advancements in immunotherapy for hepatocellular carcinoma 142
Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. 142
A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma 141
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 140
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial 138
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 137
Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5) 137
Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting 135
Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. 134
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 133
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis 132
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy 131
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 131
TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma 130
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers 130
The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool? 128
SAT-453-Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma 128
Totale 18.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021446 0 0 0 0 0 0 0 0 0 0 0 446
2021/20222.065 139 42 94 108 175 112 50 167 106 154 646 272
2022/20232.589 230 357 126 305 164 212 164 133 441 67 170 220
2023/20241.049 49 141 76 77 112 216 84 86 65 73 48 22
2024/20254.410 168 424 415 295 515 215 545 176 108 317 348 884
2025/202612.258 1.107 1.202 948 810 1.045 483 1.702 444 2.342 886 632 657
Totale 26.170